User menu

Accès à distance ? S'identifier sur le proxy UCLouvain

The Belgian 2010 consensus recommendations for the treatment of multiple myeloma

Primary tabs

Schots, R Delforge, M André, Marc [MGD] Bries, G Caers, J Doyen, Chantal [MGD]

Since the introduction of novel therapeutic agents including thalidomide, lenalidomide and bortezomib, the prognosis of multiple myeloma (MM) has significantly improved. These agents have been incorporated into numerous treatment schedules for newly diagnosed as well as more advanced MM patients. Hence, the therapeutic options for MM have become more complex and subject to rapid changes. The multiple myeloma study group (MMSG) of the Belgian Hematological Society has established recommendations for the treatment of MM as based on an extensive review of the literature which is also summarized in this paper. The recommendations are the result of a consensus opinion between haematologists with experience in the field and representing most haematology centres in Belgium. Where applicable, reimbursement criteria are also taken into account. The consensus recommendations should be a reference for use by clinical haematologists in daily practice.

Document type Article de périodique (Journal article)
Publication date 2010
Language Anglais
Journal information "Acta Clinica Belgica" - Vol. 65, no. 4, p. 252-264 (2010)
Peer reviewed yes
Publisher Acta Clinica Belgica ((Belgium) Ghent)
issn 1784-3286
Publication status Publié
Affiliation UCL - (MGD) Service d'hématologie
MESH Subject Antineoplastic Agents ; Antineoplastic Combined Chemotherapy Protocols ; Belgium ; Humans ; Immunosuppressive Agents ; Multiple Myeloma ; Salvage Therapy ; Stem Cell Transplantation
Links
  1. Kyle R. A., Rajkumar S. V., Multiple myeloma, 10.1182/blood-2007-10-078022
  2. Kyle Robert A., Remstein Ellen D., Therneau Terry M., Dispenzieri Angela, Kurtin Paul J., Hodnefield Janice M., Larson Dirk R., Plevak Matthew F., Jelinek Diane F., Fonseca Rafael, Melton Lee Joseph, Rajkumar S. Vincent, Clinical Course and Prognosis of Smoldering (Asymptomatic) Multiple Myeloma, 10.1056/nejmoa070389
  3. Avet-Loiseau Hervé, Role of genetics in prognostication in myeloma, 10.1016/j.beha.2007.08.005
  4. Hideshima Teru, Mitsiades Constantine, Tonon Giovanni, Richardson Paul G., Anderson Kenneth C., Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets, 10.1038/nrc2189
  5. Terpos Evangelos, Eleutherakis-Papaiakovou Vangelis, Dimopoulos Meletios-Athanassios, Clinical implications of chromosomal abnormalities in multiple myeloma, 10.1080/10428190500464104
  6. Podar K, Chauhan D, Anderson K C, Bone marrow microenvironment and the identification of new targets for myeloma therapy, 10.1038/leu.2008.259
  7. Kumar S. K., Rajkumar S. V., Dispenzieri A., Lacy M. Q., Hayman S. R., Buadi F. K., Zeldenrust S. R., Dingli D., Russell S. J., Lust J. A., Greipp P. R., Kyle R. A., Gertz M. A., Improved survival in multiple myeloma and the impact of novel therapies, 10.1182/blood-2007-10-116129
  8. Smith Alastair, Wisloff Finn, Samson Diana, , Guidelines on the diagnosis and management of multiple myeloma 2005, 10.1111/j.1365-2141.2005.05867.x
  9. Grignani G, Gobbi PG, Formisano R, Pieresca C, Ucci G, Brugnatelli S, Riccardi A, Ascari E, A prognostic index for multiple myeloma, 10.1038/bjc.1996.212
  10. Hjorth Martin, Hellquist Louise, Holmberg Erik, Magnusson Bengt, Rödjer Stig, Westin Jan, Initial versus deferred melphalan-prednisone therapy for asymptomatic multiple myeloma stage I - A randomized study, 10.1111/j.1600-0609.1993.tb00148.x
  11. Musto Pellegrino, Falcone Antonietta, Sanpaolo Grazia, Bodenizza Carlo, Cascavilla Nicola, Melillo Lorella, Calzulli Potito Rosario, Del l'olio Matteo, La Sala Antonio, Mantuano Saverio, Nobile Michele, Carella Angelo Michele, Pamidronate Reduces Skeletal Events but does not Improve Progression-free Survival in Early-stage Untreated Myeloma: Results of a Randomized Trial, 10.3109/10428190309178778
  12. Attal Michel, Harousseau Jean-Luc, Stoppa Anne-Marie, Sotto Jean-Jacques, Fuzibet Jean-Gabriel, Rossi Jean-François, Casassus Philippe, Maisonneuve Hervé, Facon Thierry, Ifrah Norbert, Payen Catherine, Bataille Régis, A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple Myeloma, 10.1056/nejm199607113350204
  13. Brenner H., Gondos A., Pulte D., Recent major improvement in long-term survival of younger patients with multiple myeloma, 10.1182/blood-2007-08-104984
  14. Facon Thierry, Mary Jean Yves, Hulin Cyrille, Benboubker Lotfi, Attal Michel, Pegourie Brigitte, Renaud Marc, Harousseau Jean Luc, Guillerm Gaëlle, Chaleteix Carine, Dib Mamoun, Voillat Laurent, Maisonneuve Hervé, Troncy Jacques, Dorvaux Véronique, Monconduit Mathieu, Martin Claude, Casassus Philippe, Jaubert Jérôme, Jardel Henry, Doyen Chantal, Kolb Brigitte, Anglaret Bruno, Grosbois Bernard, Yakoub-Agha Ibrahim, Mathiot Claire, Avet-Loiseau Hervé, Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99–06): a randomised trial, 10.1016/s0140-6736(07)61537-2
  15. Hulin Cyrille, Facon Thierry, Rodon Philippe, Pegourie Brigitte, Benboubker Lotfi, Doyen Chantal, Dib Mamoun, Guillerm Gaelle, Salles Bruno, Eschard Jean-Paul, Lenain Pascal, Casassus Philippe, Azaïs Isabelle, Decaux Olivier, Garderet Laurent, Mathiot Claire, Fontan Jean, Lafon Ingrid, Virion Jean Marc, Moreau Philippe, Efficacy of Melphalan and Prednisone Plus Thalidomide in Patients Older Than 75 Years With Newly Diagnosed Multiple Myeloma: IFM 01/01 Trial, 10.1200/jco.2008.21.0948
  16. Palumbo Antonio, Falco Patrizia, Corradini Paolo, Falcone Antonietta, Di Raimondo Francesco, Giuliani Nicola, Crippa Claudia, Ciccone Giovannino, Omedè Paola, Ambrosini Maria Teresa, Gay Francesca, Bringhen Sara, Musto Pellegrino, Foà Robin, Knight Robert, Zeldis Jerome B., Boccadoro Mario, Petrucci Maria Teresa, Melphalan, Prednisone, and Lenalidomide Treatment for Newly Diagnosed Myeloma: A Report From the GIMEMA—Italian Multiple Myeloma Network, 10.1200/jco.2007.12.3463
  17. Diamond Terrence H., Hartwell Tabitha, Clarke William, Manoharan Arumugam, Percutaneous vertebroplasty for acute vertebral body fracture and deformity in multiple myeloma: a short report, 10.1111/j.1365-2141.2004.04809.x
  18. Palumbo A, Rajkumar S V, Dimopoulos M A, Richardson P G, San Miguel J, Barlogie B, Harousseau J, Zonder J A, Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Bladé J, Kyle R, Westin J, Weber D, Bringhen S, Niesvizky R, Waage A, von Lilienfeld-Toal M, Lonial S, Morgan G J, Orlowski R Z, Shimizu K, Anderson K C, Boccadoro M, Durie B G, Sonneveld P, Hussein M A, Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma, 10.1038/sj.leu.2405062
  19. San Miguel Jesús F., Schlag Rudolf, Khuageva Nuriet K., Dimopoulos Meletios A., Shpilberg Ofer, Kropff Martin, Spicka Ivan, Petrucci Maria T., Palumbo Antonio, Samoilova Olga S., Dmoszynska Anna, Abdulkadyrov Kudrat M., Schots Rik, Jiang Bin, Mateos Maria-Victoria, Anderson Kenneth C., Esseltine Dixie L., Liu Kevin, Cakana Andrew, van de Velde Helgi, Richardson Paul G., Bortezomib plus Melphalan and Prednisone for Initial Treatment of Multiple Myeloma, 10.1056/nejmoa0801479
  20. Mateos MV, ASH Annual Meet-ing Abstracts, 114, 3 (2009)
  21. Palumbo A, Blood, 114, 58 (2009)
  22. Dimopoulos MA, Study.J.Clin.Oncol (2009)
  23. Chang Hong, Trieu Young, Qi Xiaoying, Xu Wei, Stewart Keith A., Reece Donna, Bortezomib therapy response is independent of cytogenetic abnormalities in relapsed/refractory multiple myeloma, 10.1016/j.leukres.2006.08.002
  24. Sagaster V, Ludwig H, Kaufmann H, Odelga V, Zojer N, Ackermann J, Küenburg E, Wieser R, Zielinski C, Drach J, Bortezomib in relapsed multiple myeloma: response rates and duration of response are independent of a chromosome 13q-deletion, 10.1038/sj.leu.2404459
  25. Combination chemotherapy versus melphalan plus prednisone as treatment for multiple myeloma: an overview of 6,633 patients from 27 randomized trials. Myeloma Trialists' Collaborative Group., 10.1200/jco.1998.16.12.3832
  26. Palumbo A, ASH Annual Meeting Abstracts, 114, 613 (2009)
  27. Facon T., Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy, 10.1182/blood-2005-04-1588
  28. Ludwig H., Hajek R., Tothova E., Drach J., Adam Z., Labar B., Egyed M., Spicka I., Gisslinger H., Greil R., Kuhn I., Zojer N., Hinke A., Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma, 10.1182/blood-2008-07-169565
  29. Morgan GJ, ASH Annual Meeting Abstracts, 114, 352 (2009)
  30. Rajkumar SV, Lancet Oncol (2009)
  31. Kapoor P., Kumar S., Fonseca R., Lacy M. Q., Witzig T. E., Hayman S. R., Dispenzieri A., Buadi F., Bergsagel P. L., Gertz M. A., Dalton R. J., Mikhael J. R., Dingli D., Reeder C. B., Lust J. A., Russell S. J., Roy V., Zeldenrust S. R., Stewart A. K., Kyle R. A., Greipp P. R., Rajkumar S. V., Impact of risk stratification on outcome among patients with multiple myeloma receiving initial therapy with lenalidomide and dexamethasone, 10.1182/blood-2009-01-202010
  32. Dispenzieri Angela, Rajkumar S. Vincent, Gertz Morie A., Lacy Martha Q., Kyle Robert A., Greipp Philip R., Witzig Thomas E., Lust John A., Russell Stephen J., Hayman Suzanne R., Kumar Shaji, Zeldenrust Steven R., Fonseca Rafael, Bergsagel P. Leif, Reeder Craig B., Stewart A. Keith, Roy Vivek, Dalton Robert J., Treatment of Newly Diagnosed Multiple Myeloma Based on Mayo Stratification of Myeloma and Risk-Adapted Therapy (mSMART): Consensus Statement, 10.1016/s0025-6196(11)61029-x
  33. Child J. Anthony, Morgan Gareth J., Davies Faith E., Owen Roger G., Bell Susan E., Hawkins Kim, Brown Julia, Drayson Mark T., Selby Peter J., High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma, 10.1056/nejmoa022340
  34. Koreth John, Cutler Corey S., Djulbegovic Benjamin, Behl Rajesh, Schlossman Robert L., Munshi Nikhil C., Richardson Paul G., Anderson Kenneth C., Soiffer Robert J., Alyea Edwin P., High-dose Therapy with Single Autologous Transplantation versus Chemotherapy for Newly Diagnosed Multiple Myeloma: A Systematic Review and Meta-analysis of Randomized Controlled Trials, 10.1016/j.bbmt.2006.09.010
  35. Lévy Vincent, Katsahian Sandrine, Fermand Jean Paul, Mary Jean Yves, Chevret Sylvie, A Meta-Analysis on Data From 575 Patients With Multiple Myeloma Randomly Assigned to Either High-Dose Therapy or Conventional Therapy : , 10.1097/01.md.0000173272.71949.a1
  36. Attal Michel, Harousseau Jean-Luc, Facon Thierry, Guilhot François, Doyen Chantal, Fuzibet Jean-Gabriel, Monconduit Mathieu, Hulin Cyrille, Caillot Denis, Bouabdallah Reda, Voillat Laurent, Sotto Jean-Jacques, Grosbois Bernard, Bataille Regis, Single versus Double Autologous Stem-Cell Transplantation for Multiple Myeloma, 10.1056/nejmoa032290
  37. Cavo M., Superiority of thalidomide and dexamethasone over vincristine-doxorubicindexamethasone (VAD) as primary therapy in preparation for autologous transplantation for multiple myeloma, 10.1182/blood-2005-02-0522
  38. Rajkumar S. Vincent, Rosiñol Laura, Hussein Mohamad, Catalano John, Jedrzejczak Wieslaw, Lucy Lela, Olesnyckyj Marta, Yu Zhinuan, Knight Robert, Zeldis Jerome B., Bladé Joan, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of Thalidomide Plus Dexamethasone Compared With Dexamethasone As Initial Therapy for Newly Diagnosed Multiple Myeloma, 10.1200/jco.2007.14.1853
  39. Lahuerta JJ, an. On-cot, 26, 5775 (2008)
  40. Lokhorst H. M., van der Holt B., Zweegman S., Vellenga E., Croockewit S., van Oers M. H., von dem Borne P., Wijermans P., Schaafsma R., de Weerdt O., Wittebol S., Delforge M., Berenschot H., Bos G. M., Jie K.-S. G., Sinnige H., van Marwijk-Kooy M., Joosten P., Minnema M. C., van Ammerlaan R., Sonneveld P., , A randomized phase 3 study on the effect of thalidomide combined with adriamycin, dexamethasone, and high-dose melphalan, followed by thalidomide maintenance in patients with multiple myeloma, 10.1182/blood-2009-05-222539
  41. Harousseau JL, Haematologica, 91, 1498 (2006)
  42. Harousseau JL, ASH Annual Meeting Abstracts, 114, 354 (2009)
  43. Cavo M, ASH Annual Meeting Abstracts, 114, 351 (2009)
  44. Lokhorst H. M., Schmidt-Wolf I., Sonneveld P., van der Holt B., Martin H., Barge R., Bertsch U., Schlenzka J., Bos G. M.J., Croockewit S., Zweegman S., Breitkreutz I., Joosten P., Scheid C., van Marwijk-Kooy M., Salwender H.-J., van Oers M. H.J., Schaafsma R., Naumann R., Sinnige H., Blau I., Delforge M., de Weerdt O., Wijermans P., Wittebol S., Duersen U., Vellenga E., Goldschmidt H., , Thalidomide in induction treatment increases the very good partial response rate before and after high-dose therapy in previously untreated multiple myeloma, 10.3324/haematol.11644
  45. Sonneveld P, ASH Annual Meeting Ab-stracts, 112, 653 (2008)
  46. Dimopoulos Meletios A., Roussou Maria, Gavriatopoulou Maria, Zagouri Flora, Migkou Magdalini, Matsouka Charis, Barbarousi Despina, Christoulas Dimitrios, Primenou Erasmia, Grapsa Irini, Terpos Evangelos, Kastritis Efstathios, Reversibility of Renal Impairment in Patients With Multiple Myeloma Treated With Bortezomib-Based Regimens: Identification of Predictive Factors, 10.3816/clm.2009.n.059
  47. Giralt S, Stadtmauer E A, Harousseau J L, Palumbo A, Bensinger W, Comenzo R L, Kumar S, Munshi N C, Dispenzieri A, Kyle R, Merlini G, San Miguel J, Ludwig H, Hajek R, Jagannath S, Blade J, Lonial S, Dimopoulos M A, Einsele H, Barlogie B, Anderson K C, Gertz M, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Sezer O, Mateos M V, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Richardson P G, Niesvizky R, Rajkumar S V, Durie B G M, International myeloma working group (IMWG) consensus statement and guidelines regarding the current status of stem cell collection and high-dose therapy for multiple myeloma and the role of plerixafor (AMD 3100), 10.1038/leu.2009.127
  48. Paripati H, Stewart A K, Cabou S, Dueck A, Zepeda V J, Pirooz N, Ehlenbeck C, Reeder C, Slack J, Leis J F, Boesiger J, Torloni A S, Fonseca R, Bergsagel P L, Compromised stem cell mobilization following induction therapy with lenalidomide in myeloma, 10.1038/sj.leu.2405100
  49. Kumar S, Dispenzieri A, Lacy M Q, Hayman S R, Buadi F K, Gastineau D A, Litzow M R, Fonseca R, Roy V, Rajkumar S V, Gertz M A, Impact of lenalidomide therapy on stem cell mobilization and engraftment post-peripheral blood stem cell transplantation in patients with newly diagnosed myeloma, 10.1038/sj.leu.2404801
  50. Mark Tomer, Stern Jessica, Furst Jessica R., Jayabalan David, Zafar Faiza, LaRow April, Pearse Roger N., Harpel John, Shore Tsiporah, Schuster Michael W., Leonard John P., Christos Paul J., Coleman Morton, Niesvizky Ruben, Stem Cell Mobilization with Cyclophosphamide Overcomes the Suppressive Effect of Lenalidomide Therapy on Stem Cell Collection in Multiple Myeloma, 10.1016/j.bbmt.2008.04.008
  51. Grignani Giovanni, Perissinotto Eliana, Cavalloni Giuliana, Carnevale Schianca Fabrizio, Aglietta Massimo, Clinical Use of AMD3100 to Mobilize CD34+ Cells in Patients Affected by Non-Hodgkin's Lymphoma or Multiple Myeloma, 10.1200/jco.2005.55.250
  52. Flomenberg N., The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone, 10.1182/blood-2005-02-0468
  53. Attal M., Harousseau J.-L., Leyvraz S., Doyen C., Hulin C., Benboubker L., Agha I. Y., Bourhis J.-H., Garderet L., Pegourie B., Dumontet C., Renaud M., Voillat L., Berthou C., Marit G., Monconduit M., Caillot D., Grobois B., Avet-Loiseau H., Moreau P., Facon T., , Maintenance therapy with thalidomide improves survival in patients with multiple myeloma, 10.1182/blood-2006-05-022962
  54. Spencer A, fain.Oncot, 27, 1788 (2009)
  55. Dimopoulos Meletios, Spencer Andrew, Attal Michael, Prince H. Miles, Harousseau Jean-Luc, Dmoszynska Anna, Miguel Jesus San, Hellmann Andrzej, Facon Thierry, Foà Robin, Corso Alessandro, Masliak Zvenyslava, Olesnyckyj Marta, Yu Zhinuan, Patin John, Zeldis Jerome B., Knight Robert D., Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma, 10.1056/nejmoa070594
  56. Richardson Paul G., Sonneveld Pieter, Schuster Michael W., Irwin David, Stadtmauer Edward A., Facon Thierry, Harousseau Jean-Luc, Ben-Yehuda Dina, Lonial Sagar, Goldschmidt Hartmut, Reece Donna, San-Miguel Jesus F., Bladé Joan, Boccadoro Mario, Cavenagh Jamie, Dalton William S., Boral Anthony L., Esseltine Dixie L., Porter Jane B., Schenkein David, Anderson Kenneth C., Bortezomib or High-Dose Dexamethasone for Relapsed Multiple Myeloma, 10.1056/nejmoa043445
  57. Weber Donna M., Chen Christine, Niesvizky Ruben, Wang Michael, Belch Andrew, Stadtmauer Edward A., Siegel David, Borrello Ivan, Rajkumar S. Vincent, Chanan-Khan Asher Alban, Lonial Sagar, Yu Zhinuan, Patin John, Olesnyckyj Marta, Zeldis Jerome B., Knight Robert D., Lenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America, 10.1056/nejmoa070596
  58. Glasmacher Axel, Hahn Corinna, Hoffmann Florian, Naumann Ralph, Goldschmidt Hartmut, Lilienfeld-Toal Marie, Orlopp Katjana, Schmidt-Wolf Ingo, Gorschluter Marcus, A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma, 10.1111/j.1365-2141.2005.05914.x
  59. Singhal Seema, Mehta Jayesh, Desikan Raman, Ayers Dan, Roberson Paula, Eddlemon Paul, Munshi Nikhil, Anaissie Elias, Wilson Carla, Dhodapkar Madhav, Zeldis Jerome, Siegel David, Crowley John, Barlogie Bart, Antitumor Activity of Thalidomide in Refractory Multiple Myeloma, 10.1056/nejm199911183412102
  60. von Lilienfeld-Toal Marie, Hahn-Ast Corinna, Furkert Kerstin, Hoffmann Florian, Naumann Ralph, Bargou Ralf, Cook Gordon, Glasmacher Axel, A systematic review of phase II trials of thalidomide/dexamethasone combination therapy in patients with relapsed or refractory multiple myeloma, 10.1111/j.1600-0609.2008.01121.x
  61. Palumbo Antonio, Bertola Alessandra, Falco Patrizia, Rosato Rosalba, Cavallo Federica, Giaccone Luisa, Bringhen Sara, Musto Pellegrino, Pregno Patrizia, Caravita Tommaso, Ciccone Giovannino, Boccadoro Mario, Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma, 10.1038/sj.thj.6200403
  62. Barlogie B., Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients, 10.1182/blood.v98.2.492
  63. van Rhee F., Bolejack V., Hollmig K., Pineda-Roman M., Anaissie E., Epstein J., Shaughnessy J. D., Zangari M., Tricot G., Mohiuddin A., Alsayed Y., Woods G., Crowley J., Barlogie B., High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis, 10.1182/blood-2007-01-067728
  64. Dimopoulos MA, J, 5, 112 (2004)
  65. García-Sanz R, González-Porras J R, Hernández J M, Polo-Zarzuela M, Sureda A, Barrenetxea C, Palomera L, López R, Grande-García C, Alegre A, Vargas-Pabón M, Gutiérrez O N, Rodríguez J A, San Miguel J F, The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed/refractory multiple myeloma, 10.1038/sj.leu.2403322
  66. Kyriakou Charalampia, Thomson Kirsty, D'Sa Shirley, Flory Angela, Hanslip Judith, Goldstone Anthony H., Yong Kwee L., Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma, 10.1111/j.1365-2141.2005.05521.x
  67. Richardson P. G., Sonneveld P., Schuster M., Irwin D., Stadtmauer E., Facon T., Harousseau J.-L., Ben-Yehuda D., Lonial S., Goldschmidt H., Reece D., Miguel J. S., Blade J., Boccadoro M., Cavenagh J., Alsina M., Rajkumar S. V., Lacy M., Jakubowiak A., Dalton W., Boral A., Esseltine D.-L., Schenkein D., Anderson K. C., Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial, 10.1182/blood-2006-08-036947
  68. Jagannath S, Haematologica, 91, 929 (2006)
  69. Kropff Martin, Bisping Guido, Schuck Elke, Liebisch Peter, Lang Nicola, Hentrich Markus, Dechow Tobias, Kröger Nicolaus, Salwender Hans, Metzner Bernd, Sezer Orhan, Engelhardt Monika, Wolf Hans-Heinrich, Einsele Hermann, Volpert Sarah, Heinecke Achim, Berdel Wolfgang E., Kienast Joachim, , Bortezomib in combination with intermediate-dose dexamethasone and continuous low-dose oral cyclophosphamide for relapsed multiple myeloma, 10.1111/j.1365-2141.2007.06656.x
  70. Kropff Martin H., Lang Nicola, Bisping Guido, Domine Nicole, Innig Georg, Hentrich Markus, Mitterer Manfred, Sudhoff Thomas, Fenk Roland, Straka Christian, Heinecke Achim, Koch Olaf M., Ostermann Helmut, Berdel Wolfgang E., Kienast Joachim, Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma, 10.1046/j.1365-2141.2003.04473.x
  71. Davies F. E., Wu P., Jenner M., Srikanth M., Saso R., Morgan G. J., The combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with comparable toxicity to velcade alone (V) and velcade plus dexamethasone (VD), 10.3324/haematol.11228
  72. Wolf J, Clin.Adv.Hematol. Oncol, 6, 755 (2008)
  73. Conner Therese M., Doan QuynhChau D., Walters Ian B., LeBlanc Annette L., Beveridge Roy A., An Observational, Retrospective Analysis of Retreatment with Bortezomib for Multiple Myeloma, 10.3816/clm.2008.n.016
  74. Orlowski Robert Z., Nagler Arnon, Sonneveld Pieter, Bladé Joan, Hajek Roman, Spencer Andrew, San Miguel Jesús, Robak Tadeusz, Dmoszynska Anna, Horvath Noemi, Spicka Ivan, Sutherland Heather J., Suvorov Alexander N., Zhuang Sen H., Parekh Trilok, Xiu Liang, Yuan Zhilong, Rackoff Wayne, Harousseau Jean-Luc, Randomized Phase III Study of Pegylated Liposomal Doxorubicin Plus Bortezomib Compared With Bortezomib Alone in Relapsed or Refractory Multiple Myeloma: Combination Therapy Improves Time to Progression, 10.1200/jco.2006.10.5460
  75. Pineda-Roman M, Zangari M, van Rhee F, Anaissie E, Szymonifka J, Hoering A, Petty N, Crowley J, Shaughnessy J, Epstein J, Barlogie B, VTD combination therapy with bortezomib–thalidomide–dexamethasone is highly effective in advanced and refractory multiple myeloma, 10.1038/leu.2008.99
  76. Palumbo A, Blood, 109, 2767 (2007)
  77. Bladé Joan, Sonneveld Pieter, San Miguel Jesús F., Sutherland Heather J., Hajek Roman, Nagler Arnon, Spencer Andrew, Robak Tadeusz, Cibeira M. Teresa, Zhuang Sen H., Harousseau Jean-Luc, Orlowski Robert Z., Pegylated Liposomal Doxorubicin plus Bortezomib in Relapsed or Refractory Multiple Myeloma: Efficacy and Safety in Patients with Renal Function Impairment, 10.3816/clm.2008.n.051
  78. Roussou Maria, Kastritis Efstathios, Migkou Magdalini, Psimenou Erasmia, Grapsa Irini, Matsouka Charis, Barmparousi Despina, Terpos Evangelos, Dimopoulos Meletios Athanasios, Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens, 10.1080/10428190801930506
  79. San-Miguel J F, Richardson P G, Sonneveld P, Schuster M W, Irwin D, Stadtmauer E A, Facon T, Harousseau J-L, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, Bladé J, Boccadoro M, Cavenagh J D, Neuwirth R, Boral A L, Esseltine D-L, Anderson K C, Efficacy and safety of bortezomib in patients with renal impairment: results from the APEX phase 3 study, 10.1038/sj.leu.2405087
  80. Richardson P. G., Blood E., Mitsiades C. S., Jagannath S., Zeldenrust S. R., Alsina M., Schlossman R. L., Rajkumar S. V., Desikan K. R., Hideshima T., Munshi N. C., Kelly-Colson K., Doss D., McKenney M. L., Gorelik S., Warren D., Freeman A., Rich R., Wu A., Olesnyckyj M., Wride K., Dalton W. S., Zeldis J., Knight R., Weller E., Anderson K. C., A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma, 10.1182/blood-2006-04-015909
  81. Reece D, Blood (2009)
  82. Stadtmauer Edward A., Weber Donna M., Niesvizky Ruben, Belch Andrew, Prince Miles H., San Miguel Jesús F., Facon Thierry, Olesnyckyj Marta, Yu Zhinuan, Zeldis Jerome B., Knight Robert D., Dimopoulos Meletios A., Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma, 10.1111/j.1600-0609.2009.01257.x
  83. Morgan Gareth J., Schey Stephen A., Wu Ping, Srikanth Muralikrishan, Phekoo Karen J., Jenner Matthew, Davies Faith E., Lenalidomide (Revlimid), in combination with cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen for myeloma patients, 10.1111/j.1365-2141.2007.06538.x
  84. Knop S., Gerecke C., Liebisch P., Topp M. S., Platzbecker U., Sezer O., Vollmuth C., Falk K., Glasmacher A., Maeder U., Einsele H., Bargou R. C., Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom), 10.1182/blood-2008-10-184135
  85. Kumar S, Lacy M Q, Dispenzieri A, Rajkumar S V, Fonseca R, Geyer S, Allmer C, Witzig T E, Lust J A, Greipp P R, Kyle R A, Litzow M R, Gertz M A, High-dose therapy and autologous stem cell transplantation for multiple myeloma poorly responsive to initial therapy, 10.1038/sj.bmt.1704545
  86. Fermand JP, Blood, 92, 3131 (1998)
  87. Bjorkstrand BB, Blood, 88, 4711 (1996)
  88. Giralt S, Aleman A, Anagnostopoulos A, Weber D, Khouri I, Anderlini P, Molldrem J, Ueno N T, Donato M, Korbling M, Gajewski J, Alexanian R, Champlin R, Fludarabine/melphalan conditioning for allogeneic transplantation in patients with multiple myeloma, 10.1038/sj.bmt.1703652
  89. Einsele Hermann, Schafer Hans-Jorg, Hebart Holger, Bader Peter, Meisner Christoph, Plasswilm Ludwig, Liebisch Peter, Bamberg Michael, Faul Christoph, Kanz Lothar, Follow-up of patients with progressive multiple myeloma undergoing allografts after reduced-intensity conditioning, 10.1046/j.1365-2141.2003.04299.x
  90. Garban F., Prospective comparison of autologous stem cell transplantation followed by dose-reduced allograft (IFM99-03 trial) with tandem autologous stem cell transplantation (IFM99-04 trial) in high-risk de novo multiple myeloma, 10.1182/blood-2005-09-3869
  91. Bruno Benedetto, Rotta Marcello, Patriarca Francesca, Mordini Nicola, Allione Bernardino, Carnevale-Schianca Fabrizio, Giaccone Luisa, Sorasio Roberto, Omedè Paola, Baldi Ileana, Bringhen Sara, Massaia Massimo, Aglietta Massimo, Levis Alessandro, Gallamini Andrea, Fanin Renato, Palumbo Antonio, Storb Rainer, Ciccone Giovannino, Boccadoro Mario, A Comparison of Allografting with Autografting for Newly Diagnosed Myeloma, 10.1056/nejmoa065464
  92. Rosinol L., Perez-Simon J. A., Sureda A., de la Rubia J., de Arriba F., Lahuerta J. J., Gonzalez J. D., Diaz-Mediavilla J., Hernandez B., Garcia-Frade J., Carrera D., Leon A., Hernandez M., Abellan P. F., Bergua J. M., San Miguel J., Blade J., , A prospective PETHEMA study of tandem autologous transplantation versus autograft followed by reduced-intensity conditioning allogeneic transplantation in newly diagnosed multiple myeloma, 10.1182/blood-2008-02-141598
  93. Bruno B., Rotta M., Patriarca F., Mattei D., Allione B., Carnevale-Schianca F., Sorasio R., Rambaldi A., Casini M., Parma M., Bavaro P., Onida F., Busca A., Castagna L., Benedetti E., Iori A. P., Giaccone L., Palumbo A., Corradini P., Fanin R., Maloney D., Storb R., Baldi I., Ricardi U., Boccadoro M., Nonmyeloablative allografting for newly diagnosed multiple myeloma: the experience of the Gruppo Italiano Trapianti di Midollo, 10.1182/blood-2008-07-167379
  94. Bensinger W I, Role of autologous and allogeneic stem cell transplantation in myeloma, 10.1038/leu.2008.396
  95. Chargari C, Eur.J.Haematol (2009)
  96. Mateos María-Victoria, Management of treatment-related adverse events in patients with multiple myeloma, 10.1016/s0305-7372(10)70009-8
  97. Mohty B., El-Cheikh J., Yakoub-Agha I., Moreau P., Harousseau J.-L., Mohty M., Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations, 10.3324/haematol.2009.012674
  98. Glasmacher Axel, Hahn Corinna, Hoffmann Florian, Naumann Ralph, Goldschmidt Hartmut, Lilienfeld-Toal Marie, Orlopp Katjana, Schmidt-Wolf Ingo, Gorschluter Marcus, A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma, 10.1111/j.1365-2141.2005.05914.x
  99. Palumbo A., Facon T., Sonneveld P., Blade J., Offidani M., Gay F., Moreau P., Waage A., Spencer A., Ludwig H., Boccadoro M., Harousseau J.-L., Thalidomide for treatment of multiple myeloma: 10 years later, 10.1182/blood-2007-10-117457
  100. Ghobrial IM, J.SupportOncol, 1, 194 (2003)
  101. Palumbo Antonio, Dimopoulos Meletios, Miguel Jesus San, Harousseau Jean-Luc, Attal Michel, Hussein Mohamad, Knop Stefan, Ludwig Heinz, von Lilienfeld-Toal Marie, Sonneveld Pieter, Lenalidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma, 10.1016/j.blre.2008.07.003
  102. Argyriou A. A., Iconomou G., Kalofonos H. P., Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature, 10.1182/blood-2008-04-149385
  103. Chanan-Khan Asher, Sonneveld Pieter, Schuster Michael W., Stadtmauer Edward A., Facon Thierry, Harousseau Jean-Luc, Ben-Yehuda Dina, Lonial Sagar, Goldschmidt Hartmut, Reece Donna, Neuwirth Rachel, Anderson Kenneth C., Richardson Paul G., Analysis of Herpes Zoster Events Among Bortezomib-Treated Patients in the Phase III APEX Study, 10.1200/jco.2007.14.9641
  104. Rotta M., Storer B. E., Sahebi F., Shizuru J. A., Bruno B., Lange T., Agura E. D., McSweeney P. A., Pulsipher M. A., Hari P., Maziarz R. T., Chauncey T. R., Appelbaum F. R., Sorror M. L., Bensinger W., Sandmaier B. M., Storb R. F., Maloney D. G., Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting, 10.1182/blood-2008-07-170746
Bibliographic reference Schots, R ; Delforge, M ; André, Marc ; Bries, G ; Caers, J ; et. al. The Belgian 2010 consensus recommendations for the treatment of multiple myeloma. In: Acta Clinica Belgica, Vol. 65, no. 4, p. 252-264 (2010)
Permanent URL http://hdl.handle.net/2078.1/123752